ŷNEWSƹNEWS׷ʤ

ƹISISλش󥿥±ǼŤƤ뤳Ȥȥ륳ǧ

ȥ륳ϡꥢƹISISƥꥹȻش󥿥±ǼŤƤ뤳Ȥǧȥ륳ǥ˥긩λλ̳ˤˤȡ󥿥ι񶭾ʤ±ǡISISشŤƤ뤳ȤҤ٤Ƥ롣

ain-al-arab-daesh-bombing


Turkey confirms that it's treating an ISIL terrorist commander injured in a bomb attack in northern Syria. 

The office of Turkeys Denizli province governor has said in a statement that a hospital in the border province of Antakya is treating Emrah C. According to the statement, the Turkish national has the right to health services. Ankara has been under fire for allowing terrorists to pass through its territory to join the ISIL in Syria and Iraq. The government has reportedly opened a hospital in the southeastern province of Gaziantep to treat the ISIL members injured while fighting in Syria.

Turkey confirms ISIL commander admitted to hospital in Antakya



̵ԤƱμŤȾΤƸԤŵåͿƤť˥åˡպʸθ»̿

ƱµǤϤʤפȺȽꡢƱԤŵåȼšɤܤ˥å»̿᡽̵

2014ǯ1220 2231ʬ

imgout

2014ǯ1219̵Գ̱ˡʺȽˤϡƱμŤȾΤƸԤŵåͿƤť˥åˡպʸθ»λʧ̿Ƚ򲼤20դǥ߰ܿʹ֤

Ϻǯ2Υݡ륵ȡɴ١ʥХɥˤǡƱšפ򸡺ɤǺǽ˥ҥåȤΤΡֽŷĿῴ󥻥󥰥󥿡פäԤˤʤȿƱ󥿡Ǻ̲ѤŵåΡּšפԤˤʤʤФ꤫Ū礭ʶˤ̣äᡢ3Ʊ󥿡ɴ٤»Ƚ򵯤

19̱ˡϡƱ¤ǤϤʤפȤƼŤɬΤΤꡣ󥻥顼Ź԰٤ԤäŷĿῴ󥻥󥰥󥿡ϡˡפ˰ȿȽǤФƱ󥿡Υ֥ȤΥȥåץڡ48֤μպʸǺܤȡ35007ߡˤ»ʧ̿ƱˡȽɴ٤ФָɥӥˤϹθ̤פǧ᤿ɴ¦ϤǤˤΥӥߤƤꡢɴ٤Фʾ٤겼Ƥ롣Խ/ܶ

ȸ 쥳ɥ㥤

imgout (1)

˦μȱ֥ƥˤäƾ뤳Ȥ

μŤ˿ʸȱ֥ƥˤäƴ򾮤뤳Ȥ

2014ǯ1129

˦μ礬ʤʤʤʤΤϡȱֵǽˤäƼʤǤȹͤƤȱֺ˦ˤäư˦Ť뤳ȤǤǽǿˤäƼ줿

⤷⤽줬¤ΤΤȤʤС˦򥳥ȥ뤹뤳ȤǽˤʤꡢĹŪʼŤ䡢֤̿ǽˤʤȸƤ롣

̾T˦CTLA4PD-1Ȥäȱֺ˦ˤä̵ƤޤΤ빳ΤѤ뤳ȤˤäơCTLA4PD-1֥åT˦˼򹶷⤵뤳Ȥ

""ȤդȤ褦ʤȤǤϤʤˤ衢ĹŪµδ֤̿ȤƤϽʬʲǽȸԤϸäƤ롣

ȱ֤ˤ뼣ˡϡޤΤˤ̤Ƥ餺ԤϲͳȤʤäƸ̤봵ԤȤǤʤԤΤˤĤơ³Ĵ³븫ߤǤ롣

ˤ衢ȱ֥ƥब˦ŨȤߤʤȤǤȤΤ礭ȯǤꡢοŸǤϡˤ϶뤳ȤΤʤ¤ˤʤ뤫⤷ʤ

ȸ ˥塼

˦ⲽȤߡ

cancerous_change_02


Multiple boosts for cancer immunotherapy

26 November 2014 3:30 pm

sn-immunotherapyH

Tumors persist and grow in part because they squelch the immune system, but researchers have recently turned the tables with treatments that prompt immune cells to hunt down malignant cells. The strategy is effective only in some patients, however, and so far has been shown to work in just a few cancer types. But studies online today in Nature reveal how one kind of immunotherapy, so-called immune checkpoint inhibitors, can be targeted to new cancers—and how doctors can single out the patients who are most likely to benefit from these drugs.

As a unit, these papers fill out many of the gaps in our understanding about these cancer immunotherapies, says Jedd Wolchok, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City who wasnt connected to the studies.

Tumors can suppress the cytotoxic T cells that would normally attack them by activating two immune cell surface receptors , CTLA4 and PD-1. But blocking CTLA4 and PD-1 with antibodies can unleash the T cells. Several clinical trials of patients with incurable cancers have shown dramatic effects from these antibodies. What we are seeing is long-term disease control, Wolchok says. In some cases, people are living long enough to die from another cause.

Researchers shy away from the c-word—cure—but they say that these immune checkpoint inhibitors could ultimately transform cancer into a manageable disease more like diabetes or HIV infection. The immune system may be able to keep the tumor in check, even if it doesnt eliminate every last cell, says cancer immunologist Drew Pardoll of Johns Hopkins University School of Medicine in Baltimore, Maryland. Prospects like that led Science to anoint cancer immunotherapy as its Breakthrough of the Year for 2013.

Yet so far, published studies have confirmed that the checkpoint inhibitors work only in kidney cancer, melanoma, and lung cancer. And even in those cancers, usually less than half of patients benefit.

In one of the new studies, a team led by oncologist Thomas Powles of Queen Mary University of London tested a new antibody created by Genentech of South San Francisco, California, in a different cancer: a difficult-to-treat form of bladder cancer. Instead of blocking PD-1 on immune cells, the antibody disables PD-L1, a protein that cancer cells and some other cells display to stimulate PD-1 and inhibit T cells. The Genentech-funded study found that the antibody shrank bladder tumors in 26% of the patients. Therapy for this type of cancer has not advanced in 25 years, notes Hopkins medical oncologist Julie Brahmer, who wasnt connected to the research. This is truly groundbreaking, she says.

In a second study, also funded by Genentech, translational oncologist Roy Herbst of the Yale School of Medicine and colleagues tested the antibody against several other kinds of incurable cancers. The patients in this trial had exhausted one, two, three lines of treatment, Herbst says, but he and his colleagues found that the antibody caused tumors to shrink in lung cancer, head and neck cancer, melanoma, and other tumor types. It is unexpected and exciting to see a single drug having an impact on so many kinds of cancer, says Suzanne Topalian, a cancer immunologist at Hopkins who didnt take part in any of the studies.

Still, fewer than 20% of the patients in the Yale trial saw their tumors dwindle. Its a big conundrum to predict who will benefit from these treatments, Herbst says. When he and his colleagues analyzed tumors from the trials patients, they found a potential explanation: variation in the amount of PD-L1 manufactured not by the cancer cells, but rather by the immune cells that had invaded the tumor. (The cancer cells may somehow compel immune cells to make the self-inhibiting molecules.) If these invading cells produced plenty of the protein, patients were more likely to respond to the antibody therapy. Testing PD-L1 levels in patients tumors might enable doctors to identify the people with the best chance of benefiting from the new antibody, Herbst says.

In a third Nature study, tumor immunologist and physician Antoni Ribas of the University of California, Los Angeles, and colleagues pinpointed another biomarker that might help improve the success rate of the immune-awakening antibodies. After poring over biopsy samples from the melanoma tumors of 46 clinical trial participants treated with a PD-1–blocking antibody, the researchers found that the best portent of treatment success was the abundance of cytotoxic T cells at the edge of the tumors. The more cells crowding into the edge of the tumor, the better.

To confirm their finding and gauge its usefulness, Ribas and colleagues then analyzed biopsy samples from melanoma patients in a clinical trial at another hospital. Using just this one feature, they correctly predicted how well 13 of the 15 patients would respond to the antibody therapy. An assay that detects the presence of [cytotoxic T] cells in tumors could be the first decision point in the treatment of patients, Ribas says.

Researchers are already looking at how to use the results of these studies to improve cancer immunotherapy, possibly by combining it with other types of treatments. The next use will be in combination with other cancer drugs to get a greater impact, Topalian says. 

Posted in Biology, Health

ȸ Science

ҵ說Ѥʤϡǯ3ߤ2475Ƥʾɾ617

ҵ說ѡθμŤǣ

2014ǯ70417:09
 
mqdefault (3)

ҵͽɥ說Ѥʤ꼡ǤǡϫƯʤθɤ̤θŤʤɤǤ褽οͤΤˤߤȤμŷ̤𤷤ޤ

ҵͽɥ說Ȥˤߤ䤷ӤʤѤʤ꼡Ǥǡϫʤ֤˸Ƥ򳫤οǻˤäƤϫʸɤΰդŷ̤𤷤ޤ

ˤȡ԰¤ȤȤ˾ɾ륱¿̤ˤθŤǡͤΤˤ룴ͤΤˤߤƤȤȤǤ

ǡҵ說ѤʤϡǯߤǣƤʾɾϣ˾äƤޤ

֤⤦줷Τϻ䤿ǽˤƤۤסѤʤҹ⹻

ϫǤϡѤʤ餬ޤꡢҵ說ܼȿФ夲ޤǯϥ說ѶŪܼƤӤǤƤޤǤϡΥ說ܼбˤĤƤäޤǤ

ȸ
TBS˥塼


ޥեʡˤε۰ϡɤ¡ɤ˸̤ꡡ褯봪㤤ס٤ˤʤפʤ

ε۰ϡ֤Ĥ˸̤פȤθ

2013ǯ829

article-2400032-1B6988BA000005DC-182_634x464

ܤϰˡΰϰǤϴʤˤ䥨μŤˤ졢ˡŪ˻ѤƤ롣㤬Ĥ䵤ʬߤ˸̤Ȥθ̤ȯɽ졢ܤ򽸤Ƥ롣

Ť˺ѤʬTHC
衼åѤǽǤ줿ػ郎THCʥƥȥҥɥʥӥΥɡˤˤϡ뤤ʬѤ̤פȯɽƤ롣ʤߤμ¸ʬ THC

THC ˤϡ˸̤ȤǾʥӥΥɤŤʬˤǽ롣äơ˴ޤޤ THC ĤμŤѤǤΤǤϤʤȤε夬äΤǤ롣

ǥϥåԡʵʬ
ǡΰ縦ब ʬФθ̡ 򸡾ڤ뤳Ȥˡޤ1ʲǯ4ʾ٤ǵ۰︳ԤȤTHC Ϳ롼פȡ THC Ϳ롼פʬ

ˡִ򤷤ʿ͡פȡֶ͡פμ̿˸줾ɽ򿿻Ƥäη̡THC Ϳ줿롼פֶ͡פ򿿻ɽϡȤƤ ȶäƤ ȤϸʤΤäȤ ȴ򤷤ʿ͡ ɽϡɽ뤳ȤǤ

ǾǤ
˼¸̤΢դ뤿ˡब︳ԤǾ򥹥󤷤ȤǾδʬ THC ͭƤ뤳Ȥ餫ˤʤäˤꡢ˴ޤޤ THC ˤϥͥƥ֤ʴ򸺾̤뤳Ȥ줿ΤǤ롣

⤷ᤤ衢ܤǤ⡢ĤǶ줷വԤˡȤ㤬뤫⤷ʤ

article-2400032-1B6988B6000005DC-379_306x289

ȸ  Mail Onlineʱʸ
ɮ  Nekolas
åȥ˥塼24

article-2400032-1B6988AB000005DC-320_634x385


ޥեʤ˴ؤ褯봪㤤8 ס٤ˤʤפʤ

2012ǯ57

marijuana

ϡ֥ޥեʡפФƤɤΤ褦ʥ᡼äƤǤϡְѥޥեʡפβؤƤ٤Ȥ⤢äƤ뤬ȺѤʤɴʥ᡼ȷդ줬ʥޥեʡ

ʲϡƥǥΥϥեȥݥȤǾҲ𤵤Ƥ֥ޥեʤ˴ؤƸ򤵤줬8ĤΤȡפǤ롣¿οͤˤʤߤʤˡ򤵤뤳Ȥ⾯ʤʤޥեʤʲɤ¿ȯϤޥեʤ򥪥ᤷƤ櫓ʤΤǴ㤤ʤ褦ˡ

ϥեȥݥȤˤ֥ޥեʤ˴ؤƸ򤵤줬8ĤΤȡ
 
1ޥեʤǤˤʤ
Ф䥳ҡƱ褦ˡޥեʤϰٵۤǤˤʤȤ褯뤬οϤʤˤäơ뤫פˤäƤѤ롣

1994ǯե˥ؤΥåإ˥󥰥եΤ륳롢˥󡢥󡢥إ󡢥ե5ĤʪȥޥեʤӤݡ¸ΥæȤˤƤϥޥեʤϺǤ㤤Ȥ̤ˤʤäեʤ¾ʪ٤СޥեʤϤޤǹ⤯ʤΤ

2ޥեʤϡʪפǤ
ޥեʤϥإȤäϡɤʥɥåλѥꥹʪפȤո뤬ʤ2008ǯ˥ޥեʤۤäȤǧ᤿ꥫͤ1520ͤäƱͤοϥ190͡إ20ͤ

2010ǯƱĴ»ܤȤޥեʤۤäͿ1740ͤäΤФơѼԤ150ͤȸإѼԤοѲʤäޥեʤʪǤСޥեʤλѼäȶˡ󡢥إλѼԤϤοϢưƤʤΤǤ롣

3ޥեʤˤϰŸ̤Ϥʤ
ޥեʤΰŪʸ̤˴ؤ븦Ͽ¿ʤƤ롣ȤСˤߤ¤餲롢Ǥޤ롢ߤʤ롢ζĥۤȤäǽĤȤ롣ꥫιΩ󸦵ϡޥեʤϤοʹԤɤ̤⤿餹ǽȤȯɽƤ롣ǽŪʷãˤϤޤޤ椬ɬפʤ褦

4ޥեʤۤ٤ˤʤ
ޥեʤϥХƱͤ٤ΥꥹȤո򼪤ˤ뤳Ȥ롣ޥեʤݼ٤ȯΨäΰ̴طȤΤϾƤʤΰ̴طɵ椹뤿˺Ǥ絬Ϥ˹Ԥ줿η̤Ǥϡ22000ܤΥޥեʤۤäȤإӡ桼Ǥ٤Υꥹޤ뷹ǧʤä

5ޥեʤˤϰͿ̤ȤΤϤʤ
ꥫܤϵʪˡȤˡΧʪƤꡢޥեʤϥ塼뭵ȤäȤ⵬θִʡʪʬवƤ롣طʤ⤢֥ޥեʤ˰Ϳ̤¸ߤʤסֵۤ᤮Ȼ˻פȹͤ뤳Ȥ롣

ºݤˤϤޤǥޥեʤεۤ᤮ǻ˻äȤΤ𤵤Ƥʤޥեʤ̿Ĥˤϡ¬ǤϤ뤬15ʬ֤680Υޥեʤݼ褹ɬפȤ롣Ϥ󡢤ɤääԲǽ̤Ǥ롣

6ޥեʤˡˤȡޥեʤۤƥ󥨥㡼
ŪǥޥեʻѤǧ뽣ǤϡޥեʤιˡФȿаոΰĤˡޥեʤˡˤȡޥեʤۤƥ󥨥㡼ΤǤϤȴ롣

Ƕθˤɬ⤽ǤϤʤ褦ѥޥեʤˡǤɥɽθԤˡǤϤʤޥ塼åĽӤȤƥ󥨥㡼ΥޥեݼΨ˺ϸʤäȤΤȤ

7ʥޥեʡˤƱΤǤ
ꥫǤʥޥեʡˤȤδطκݤػߤƤ뤬θǤ륫ʥӥƱ°οʪǤΤΡۤʤ뿢ʪ

μʬǤǥ륿ݣݥƥȥҥɥʥӥΡTHCˤȤϥʾ֤ˤѤʪ¿ޤޤʤʥӥǥȤTHCκѤ˳Ȥʪ¿ޤǤ롣ΤᡢȰäơۤäƤϥˤʤ뤳ȤϤʤΤ

8ޥեʤµŤǤ
ޥեʤˤ϶ˤ¤餲̤ꡢ߸ǤζĥˤȤ롣ѥޥեʤǧƤ뽣ˤƤ⡢ԤϹˡŪ˥ޥեʤ뤳ȤϤǤʤֿ侩פȤǤΤ

ȤΤ⡢Ūʸ̤ʤȤ륹塼뭵ɥå˥ޥեʤäƤ뤫εˤäơޥեʤϰŸ̤¾ڤ뤿׾­˹ԤȤǤʤΤǤ롣

ġİʾ塢ϥեȥݥȤˤ֥ޥեʤ˴ؤƸ򤵤줬8ĤΤȡפǤ롣ɤǤߤȥޥեʤꤷޤäƤ뤬ˡΧǶػߤƤʾϡ褷ƼФƤϤʤ

ʸẴƣ 椭

ȸ  The Huffington Postʱʸ
åȥ˥塼24


ޥեʤϴμ˦򻦤˸ø

ޥեʤϤݤø!?

2012.9.26 20:36
 
wir12092620370005-p1

ޥեʤϤμ˦򻦤˸ˡΤ褦˲ŪѤ⤿餵ʤ椬ޥեʤ˴ޤޤ륫ʥӥǥTHCͭ΢դ

Ԥδ֤Ǥϡޥեʤ¸ߤ륫ʥӥǥCBDˤȤʪ˦Ĺ٤餻Ƥ˦η˸뤿ᡢ䤽žܤƮΤΩĤȤοޤäƤ롣ͭ΢դ뿷椬Τʪˤߤ䡢Ǥ䡢µ䲽ˡѤ¤뤳ȤϤǤΤƤ롣

Newsweek٤Ƥ褦ˡǤ2007ǯ˥ե˥ѥեåť󥿡Τ븦椬ʥӥǥ뤬󴵼Ԥμ˦ɤΤ褦˻˲ơµۤκ˦žܤ뤦ǸȤʤ̤ѥID-1ҤΥå򥪥դˤ뤫򼨤Ƥ

ΰҤϡ򹯤ʸΤˤƤϡȯδ֤Τ߳ư롣䡢¾οʹԤˤäͤˤƤϡΰҤươµΤۤη򹯤ʺ˦ؤΰܹԤơžܤȤѻ줿

֤ΰҤ빶Ūʼ10ޤ¸ߤפȡԤƤ롣ơʥӥǥϤߤ뤳ȤǤ롣äơΤʤϤʼˡȤʤ롣ˡΤ褦µߤ뤱ɡ뤢κ˦򻦤¿ͤΤ˲벽ˡȰäơΰ˦Τߤ֥å뤳ȤǤΤ

֥ʥӥǥϲͤδԤˡŤδ˾Ϳפȡ楰롼פΥ꡼̳᤿ԡޥꥹϽҤ٤衢漼Ǵѻ줿̤ΤǸڤ뤿ɬפ׾ϤޤԤƤʤ

ޥꥹϤޤ󴵼Ԥˤμˡθ̤ƥȤ뤿λõƤ롣δθ楰롼פϡ漼ǥʥӥǥܤˤˡ򲽳ˡȤ߹碌뤳ȤǽͭפɤʬϤƤ롣θϡʥӥǥθ̤Τ褦ˤƶ뤳Ȥ򤹤Ǥ˾ѤߤƲˡϤ궯Ϥʸ̤ߡդϾʤʤ롣ȤΤ⡢̤Ū˸餹Ȥǽ

ʪθ̤ȯΤϡޥɥ꡼ɤΥץƥؤʪؼԡꥹƥʡǾμ˦ʬϤ뤳Ȥǡ˦οդ򸦵椷Ƥ̤κ˦⤺ä®Ĺ롣ϡκ˦ƥȥҥɥʥӥΡ˻ȤĤǤ뤳Ȥ˶դޥեʤθѤͭ̾THCΤȤ

ϸ³1998ǯˤȯɽơTHCǾΤȤ櫓Ūʷ֤ĺ˦ΥݥȡʤͶȯ뤳Ȥ³ơ¿΢դޤޤʹǹԤ줿THC䤽¾ΥޥեʤʪᥫʥӥΥɤϡľŪʹ̤äƤ뤳Ȥ狼äƤ롣

ʹ֤Фǽ׾2006ǯ˥ڥǹԤ줿ԤTHCŪʼˡϲäʤä9ͤǾ紵ԤͿơƥľܡµˤä˦THC9ˤƼषȤѻ졢η̤ϡNature٤˷Ǻܤ줿

δ֤ˡϡؤθԤϡ٤ФƤƱ̤뤳Ȥȯ餬ܤǤä٤ȤϡTHC˦ΤߤǷͿ򹯤ʺ˦⤵뤳ȤϤʤäȤ¤

θ塢ɥΥȡ硼ؤκǶθϡ¤ФƤƱ̤׾ˤäƴѻǯ7ɥĤΥե饤֥륯ǹԤ줿ǶιݥʥӥΥɸǤϡΥơޤκǤͭ̾ȤҤȤĤΥơ֥Ϥ

˶̣׸ꥢθԤ⤢ꡢϥʥӥΥɤΩˤ˦νΤѤǤǤ⶯ϤפɾޤꥹΥ󥫥ؤθԤϡIJμ˴ؤƤƱͤη𤷤

餹٤ƤϡȤ襤ˤƿͭ˾ƻڤ򳫤ϤääƤͤФʤʤΤϡѤĥɥåȸʤƤ륫ʥӥΡְŪʡ׻ѤˤŪʪŪʱƶϡľŪ˸ʪݼ褹뤳ȤˤʤǤʤǮʬ򡢤ʤ洬ΡХפdzƤβ߽Ф뤽¾ʪˤ붼Ҥ˻뤳ȤˤĤʤȤȤ

ºݡޥեʤϥդȤȯϡǡúǡʪ˥ȥߥޤǤ롣ޤͷγҾʪϡեΡ롢쥾롢Ƥޤޤ˧²úǡŪȯʪޤǤ롣

ȸ
WIRED








ҶΤ¼ŪǺ줿3Dե󥿥ֶðۤμŸ̡

ðۤμŸ̡Ҥɤ⤿Τ¼ŤΤ˺줿3Dե󥿥ब

2012ǯ429

¿δԤ֤¡סΤ¤ͤǤϤʤҤɤˤȯɤƤꡢ¿οͤοµƮäƤ롣

ƺ󡢤¤˶줷Ҥɤ⤿εȤʤ뤫⤷ʤ륲बо줷礭ƤǤ롣Υ̾ϡSPARXס

¤ξɾ򾯤ʤȤ3ʬ1ϸ餹Ȥ3Dե󥿥ϡؤǯ¤ΥڥꥹȤȯ

ƥץ쥤䡼ϼʬΥХʬȥ饯ˤ򥫥ޥǤ褦ˤʤäƤꡢ͡ʲ꤬Ѱդ줿7Ĥΰ˹Ԥ褹뤳ȤǽΤʤŪʻ׹ͤؤнˡʤɡ¤ƮΤɬפʤȤؤ٤ȤߤˤʤäƤΤ

֤áʤ󤫤Ǥ¤Ρפ¿οͤ˻פä⤷ʤΥϽ̥󥻥󥰤˾Ȥʤ餷Ÿ̤äƤ餷

˥塼ɤ187ͤμԤоݤĴԤäȤSPARX 7ĤβΤ4İʾ򥯥ꥢ︳ԤΤʤ44ѡȤ¤鴰Ȥä٤ơ̥󥻥󥰤ƴͤ26ѡȤǤä

ޤSPARXץ쥤95ѡȤ︳ԤΥ¾10ˤ81ѡȤͧã᤿äƤ롣Ϥ⤷ǯ¼Ťˡ̿򵯤⤷ʤͽƤ븦̤Ǥ롣

ʤߤ˸Ԥϡᤤ꡼ܻؤƥγȯǤȤΤȡΤʤǤϤʤ֥ץ쥤䡼פߤȤ˽Ť֤βŪʥϡ˰Τɤʾ׷ͿΤδȤƤڤߤǤ롣

ʸϯ
ȸ:SPARX׸
Daily Mailʱʸ
YouTube/SPARXNewZealand
åȥ˥塼
http://rocketnews24.com/2012/04/29/206069/

 
͵֥󥭥󥰤







QR
QR
  • 饤֥ɥ֥